Week's Worth of HIV Meds in a Single-Dose Capsule Feasible

Share this content:
Week's Worth of HIV Meds in a Single-Dose Capsule Feasible
Week's Worth of HIV Meds in a Single-Dose Capsule Feasible

TUESDAY, Jan. 9, 2018 (HealthDay News) -- A novel oral dosage form enables sustained release of antiretrovirals, allowing delivery for up to one week after a single administration, according to a study published online Jan. 9 in Nature Communications.

Ameya R. Kirtane, Ph.D., from the Massachusetts Institute of Technology in Cambridge, and colleagues describe a modular drug delivery system, which folds and recoils, allowing oral dosing and retains its integrity in the stomach for prolonged residence. The system can be loaded with up to six formulations, and was used to deliver three antiretrovirals: dolutegravir, rilpivirine, and cabotegravir in a pig model.

The researchers found that the orally-administered platform delivered three antiretrovirals for up to seven days after a single administration, with week-long systemic drug levels identified. Based on simulation of viral dynamics and patterns of patient adherence, such a system would reduce therapeutic failure. This intervention could prevent hundreds of thousands of new HIV cases prophylactically, based on epidemiological modeling.

"Weekly administration of long-acting antiretrovirals via a novel oral dosage form is a promising intervention to help control the HIV epidemic worldwide," the authors write.

Several authors disclosed financial ties to Lyndra.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »